NSE / BSEHealthcare
β‚Ή818.30+3.85+0.47%
P/E35.5Mkt Capβ‚Ή15.77 K CrEV/EBITDA15.2

ALEMBIC PHARMACEUTICALS LIMITED

P/E35.5Mkt Capβ‚Ή15.77 K CrEV/EBITDA15.2
Company Profile

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 18.48% over 1Y
Monthly Returns

Historically, Apr has averaged the highest return (+5.5%); Feb the lowest (-6.3%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-7.9%Negative MonthJan 2026: -7.85%-9.0%Negative MonthFeb 2026: -8.96%-7.0%Negative MonthMar 2026: -6.98%+14.0%Positive MonthApr 2026: +14.00%-2.6%Negative MonthMay 2026: -2.57%+12.0%Positive MonthJun 2026: +12.03%-0.6%*Neutral MonthJul 2026: -0.64%β€”β€”β€”β€”β€”
2025-13.5%Negative MonthJan 2025: -13.54%-19.2%Negative MonthFeb 2025: -19.16%+24.9%Positive MonthMar 2025: +24.93%-5.7%Negative MonthApr 2025: -5.69%+16.1%Positive MonthMay 2025: +16.07%+2.5%Positive MonthJun 2025: +2.50%-6.2%Negative MonthJul 2025: -6.20%-4.2%Negative MonthAug 2025: -4.18%-3.9%Negative MonthSep 2025: -3.94%-0.4%Neutral MonthOct 2025: -0.39%+1.2%Neutral MonthNov 2025: +1.18%-6.5%Negative MonthDec 2025: -6.51%
2024+26.4%Positive MonthJan 2024: +26.38%+6.0%Positive MonthFeb 2024: +6.01%-3.5%Negative MonthMar 2024: -3.48%+1.5%Neutral MonthApr 2024: +1.47%-7.4%Negative MonthMay 2024: -7.40%-5.0%Negative MonthJun 2024: -5.05%+34.6%Positive MonthJul 2024: +34.62%-10.1%Negative MonthAug 2024: -10.14%+13.7%Positive MonthSep 2024: +13.69%-6.4%Negative MonthOct 2024: -6.35%-3.5%Negative MonthNov 2024: -3.50%-2.3%Negative MonthDec 2024: -2.30%
2023-6.1%Negative MonthJan 2023: -6.10%-5.2%Negative MonthFeb 2023: -5.21%-2.8%Negative MonthMar 2023: -2.76%+12.3%Positive MonthApr 2023: +12.27%-1.6%Neutral MonthMay 2023: -1.63%+16.1%Positive MonthJun 2023: +16.15%+21.7%Positive MonthJul 2023: +21.65%+0.4%Neutral MonthAug 2023: +0.36%+0.9%Neutral MonthSep 2023: +0.93%-9.0%Negative MonthOct 2023: -9.03%+4.6%Positive MonthNov 2023: +4.60%+1.8%Neutral MonthDec 2023: +1.84%
2022-5.7%Negative MonthJan 2022: -5.73%-4.1%Negative MonthFeb 2022: -4.14%+2.2%Positive MonthMar 2022: +2.21%+5.4%Positive MonthApr 2022: +5.42%-6.2%Negative MonthMay 2022: -6.17%-0.3%Neutral MonthJun 2022: -0.32%-4.1%Negative MonthJul 2022: -4.07%-7.6%Negative MonthAug 2022: -7.57%-6.8%Negative MonthSep 2022: -6.76%-9.0%Negative MonthOct 2022: -8.99%+8.2%Positive MonthNov 2022: +8.19%-3.7%Negative MonthDec 2022: -3.69%
2021β€”β€”β€”β€”β€”+4.4%Positive MonthJun 2021: +4.42%-19.9%Negative MonthJul 2021: -19.92%-4.6%Negative MonthAug 2021: -4.64%+5.0%Positive MonthSep 2021: +5.01%-1.4%Neutral MonthOct 2021: -1.45%+3.7%Positive MonthNov 2021: +3.73%-0.5%Neutral MonthDec 2021: -0.46%
AvgΒ±SD-1.4%Β±14.2%-6.3%Β±8.1%+2.8%Β±11.5%+5.5%Β±7.2%-0.3%Β±8.5%+5.0%Β±7.2%+4.2%Β±18.3%-5.2%Β±3.5%+1.8%Β±7.2%-5.2%Β±3.7%+2.8%Β±3.9%-2.2%Β±2.8%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 0.965x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή6.03 K Crβ–² 2.7%
EBITDA Growthβ€”
Net Profitβ‚Ή503.00 Crβ–Ό 24.5%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–² 200.0%
Revenue CAGR 5Y7.3%
EBITDA CAGR 5Y-5.0%
Net Profit CAGR 5Y-7.2%
NP Growth 1Y-24.5%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή6.03 K Crβ€”β‚Ή503.00 Crβ€”β€”9.7%2.7%-24.5%
Mar 2024β‚Ή5.87 K Crβ€”β‚Ή666.00 Crβ€”β€”13.6%14.1%91.9%
Mar 2023β‚Ή5.15 K Crβ€”β‚Ή347.00 Crβ€”β€”7.9%2.3%-36.2%
Mar 2022β‚Ή5.04 K Crβ€”β‚Ή544.00 Crβ€”β€”10.3%-0.6%-50.4%
Mar 2021β‚Ή5.07 K Crβ€”β‚Ή1.10 K Crβ€”β€”21.5%22.6%13.2%
Mar 2020β‚Ή4.13 K Crβ€”β‚Ή969.00 Crβ€”β€”29.0%12.9%58.6%
Mar 2019β‚Ή3.66 K Crβ€”β‚Ή611.00 Crβ€”β€”22.5%24.3%44.8%
Mar 2018β‚Ή2.94 K Crβ€”β‚Ή422.00 Crβ€”β€”19.2%-1.4%-2.1%
Mar 2017β‚Ή2.99 K Crβ€”β‚Ή431.00 Crβ€”β€”23.1%-0.8%-38.3%
Mar 2016β‚Ή3.01 K Crβ€”β‚Ή699.00 Crβ€”β€”45.7%49.0%143.6%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales1,8442,0193,0092,9862,9453,6604,1335,0675,0355,1495,8746,0336,267
Total Expenses1,4851,6112,0262,3532,3132,7822,9303,6184,1274,4844,8755,1315,400
EBIT / Operating Profit3594089836336338791,2031,449909665999901868
OPM %19%20%33%21%21%24%29%29%18%13%17%15%14%
Other Income43737612584513316148
Finance Costs1034321525131749547691
Depreciation & Amortisation40447283102106136183285273271277287
Profit Before Tax3123639145505357651,1671,338658346704609537
Tax %24%21%24%22%21%20%17%18%17%-0%5%17%-
Net Profit / PAT2382876994314226119691,097544347666503444
EPS (β‚Ή)12.6415.2037.0622.8422.3832.4251.4255.7927.6517.6433.9125.6022.59
Dividend Payout %24%23%11%18%18%17%19%25%36%45%32%43%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
ALEMBIC PHARMACEUTICALS LIMITEDthis co.β‚Ή15.77 K Crβ‚Ή6.03 K Cr35.503.0015.182.7%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of ALEMBIC PHARMACEUTICALS LIMITED and the metrics that matter.

Browse the full Equiscale Academy